FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2001051978> ?p ?o ?g. }

• W2001051978 abstract "HomeCirculationVol. 115, No. 12Letter by Cen Regarding Article, “Effect of Celecoxib on Cardiovascular Events and Blood Pressure in Two Trials for the Prevention of Colorectal Adenomas” Free AccessLetterPDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessLetterPDF/EPUBLetter by Cen Regarding Article, “Effect of Celecoxib on Cardiovascular Events and Blood Pressure in Two Trials for the Prevention of Colorectal Adenomas” Ye-Ying Cen, MHSc Ye-Ying CenYe-Ying Cen Department of Medicine, Hennepin County Medical Center, Minneapolis, Minn Search for more papers by this author Originally published27 Mar 2007https://doi.org/10.1161/CIRCULATIONAHA.106.672097Circulation. 2007;115:e348To the Editor:I read with interest the paper by Solomon et al1 in which the authors have combined the analysis results of 2 independent trials, Adenoma Prevention With Celecoxib (APC)2 and Prevention of Colorectal Sporadic Adenomatous Polyps (PreSAP),3 in an attempt to estimate cardiovascular events (CVs) associated with celecoxib across 3 different dose regimens. I am concerned about the validity of their combined analysis and their conclusion that celecoxib at 200 or 400 mg twice daily (APC) or at 400 mg once daily (PreSAP) showed a nearly 2-fold increase in CV risk.First, patients in APC differed significantly from patients in PreSAP regarding some very important baseline clinical characteristics—including prevalence of hypertension, smoking, low-dose aspirin use, and lipid-lowering drug use—that are known to be possible predictors of CV events. For example, 414 patients (31%) in APC were on low-dose aspirin compared with 159 patients (17%) in PreSAP. Five hundred sixteen patients (38%) in APC were on lipid-lowering drugs compared with 159 patients (17%) in PreSAP. We do not know whether increased CV events in APC were caused by drug interactions with celecoxib. We do know that CV risk was the greatest for patients with a history of CVs at baseline.To justify a combined hazard ratio, the authors ran 2 Cox models to compare the 2 dose arms in APC and to compare APC with PreSAP. The large differences among the hazard ratios (3.4, 2.6, and 1.3) made it unconvincing that one could combine those results, even though the heterogeneity tests were insignificant. The relatively small probability value (0.13) suggests some difference. It may not be appropriate to apply the conclusion drawn from the combined estimate to both patient populations.My other concerns involve modeling issues. The authors do not report the interactions between low-dose aspirin use with celecoxib or between lipid-lowering drugs with celecoxib. Furthermore, we do not know how their stratified model was derived and which covariates were included. We also do not know which covariates were used for the 2 Cox models to generate the 2 hazard ratios that they combined.With access to complete data from both trials, the authors could have performed a much more rigorous and comprehensive statistical analysis by fitting a Cox regression model to the entire data from both trials. In this model, with complete data, the authors could have formally tested the validity of combining the 3 dose regimens and derived a more statistically sound combined hazard ratio for the entire dataset. Furthermore, the authors could have potentially investigated the dose effect, and this might have provided a better summary of the drug safety.The authors have made an important contribution to our understanding of the adverse effects of celecoxib at 400- and 800-mg doses. I look forward to additional results from their collaboration.DisclosuresNone.1 Solomon SD, Pfeffer MA, McMurray JJV, Fowler R, Finn P, Levin B, Eagle C, Hawk E, Lechuga M, Zauber AG, Bertagnolli MM, Arber N, Wittes J; APC and PreSAP Trial Investigators. Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas. Circulation. 2006; 114: 1028–1035.LinkGoogle Scholar2 Bertagnolli MM, Eagle CJ, Zauber AG, Redston M, Solomon SD, Kim K, Tang J, Rosenstein RB, Wittes J, Corle D, Hess TM, Woloj M, Boisserie F, Anderson WF, Viner JF, Bagheri D, Gordon GB, Burn J, Chung DC, Dewar T, Folwy TR, Hoffman N, Macrae, F, Pruitt RE, Salzman B, Tylwestrowicz T, Hawk ET; for the APC study Investigators. Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med. 2006; 355 (9): 873–884.CrossrefMedlineGoogle Scholar3 Arber N, Eagle CJ, Spicak J, Racz I, Dite P, Hajer J, Zavoral M, Lechuga MJ, Gerletti P, Tang J, Rosenstein RB, Macdonald K, Bhadra P, Fowler R, Wittes J, Zauber AG, Solomon SD, Levin B; for PreSAP Trial Investigators. Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med. 2006; 355 (9): 885–895.CrossrefMedlineGoogle Scholar Previous Back to top Next FiguresReferencesRelatedDetails March 27, 2007Vol 115, Issue 12 Advertisement Article InformationMetrics https://doi.org/10.1161/CIRCULATIONAHA.106.672097PMID: 17389275 Originally publishedMarch 27, 2007 PDF download Advertisement SubjectsCerebrovascular Disease/StrokeCongenital Heart DiseaseMyocardial Infarction" @default.
• W2001051978 created "2016-06-24" @default.
• W2001051978 creator A5089363919 @default.
• W2001051978 date "2007-03-27" @default.
• W2001051978 modified "2023-10-14" @default.
• W2001051978 title "Letter by Cen Regarding Article, “Effect of Celecoxib on Cardiovascular Events and Blood Pressure in Two Trials for the Prevention of Colorectal Adenomas”" @default.
• W2001051978 cites W1982248155 @default.
• W2001051978 cites W2130517249 @default.
• W2001051978 cites W2134234269 @default.
• W2001051978 doi "https://doi.org/10.1161/circulationaha.106.672097" @default.
• W2001051978 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17389275" @default.
• W2001051978 hasPublicationYear "2007" @default.
• W2001051978 type Work @default.
• W2001051978 sameAs 2001051978 @default.
• W2001051978 citedByCount "0" @default.
• W2001051978 crossrefType "journal-article" @default.
• W2001051978 hasAuthorship W2001051978A5089363919 @default.
• W2001051978 hasBestOaLocation W20010519781 @default.
• W2001051978 hasConcept C121608353 @default.
• W2001051978 hasConcept C126322002 @default.
• W2001051978 hasConcept C143998085 @default.
• W2001051978 hasConcept C2776467144 @default.
• W2001051978 hasConcept C2776861080 @default.
• W2001051978 hasConcept C2777428134 @default.
• W2001051978 hasConcept C2777628954 @default.
• W2001051978 hasConcept C2780814781 @default.
• W2001051978 hasConcept C526805850 @default.
• W2001051978 hasConcept C535046627 @default.
• W2001051978 hasConcept C71924100 @default.
• W2001051978 hasConcept C84393581 @default.
• W2001051978 hasConcept C90924648 @default.
• W2001051978 hasConceptScore W2001051978C121608353 @default.
• W2001051978 hasConceptScore W2001051978C126322002 @default.
• W2001051978 hasConceptScore W2001051978C143998085 @default.
• W2001051978 hasConceptScore W2001051978C2776467144 @default.
• W2001051978 hasConceptScore W2001051978C2776861080 @default.
• W2001051978 hasConceptScore W2001051978C2777428134 @default.
• W2001051978 hasConceptScore W2001051978C2777628954 @default.
• W2001051978 hasConceptScore W2001051978C2780814781 @default.
• W2001051978 hasConceptScore W2001051978C526805850 @default.
• W2001051978 hasConceptScore W2001051978C535046627 @default.
• W2001051978 hasConceptScore W2001051978C71924100 @default.
• W2001051978 hasConceptScore W2001051978C84393581 @default.
• W2001051978 hasConceptScore W2001051978C90924648 @default.
• W2001051978 hasIssue "12" @default.
• W2001051978 hasLocation W20010519781 @default.
• W2001051978 hasLocation W20010519782 @default.
• W2001051978 hasOpenAccess W2001051978 @default.
• W2001051978 hasPrimaryLocation W20010519781 @default.
• W2001051978 hasRelatedWork W1982947700 @default.
• W2001051978 hasRelatedWork W2095364230 @default.
• W2001051978 hasRelatedWork W2137839634 @default.
• W2001051978 hasRelatedWork W2152801232 @default.
• W2001051978 hasRelatedWork W2328977712 @default.
• W2001051978 hasRelatedWork W2347824894 @default.
• W2001051978 hasRelatedWork W4362567567 @default.
• W2001051978 hasRelatedWork W4362567707 @default.
• W2001051978 hasRelatedWork W1691189393 @default.
• W2001051978 hasRelatedWork W4200636047 @default.
• W2001051978 hasVolume "115" @default.
• W2001051978 isParatext "false" @default.
• W2001051978 isRetracted "false" @default.
• W2001051978 magId "2001051978" @default.
• W2001051978 workType "article" @default.